Derek Dinart

Dr. Derek Dinart


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MSMarion Savina
Marion Savina
SGSophie Gourgou
Sophie Gourgou
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
DDDerek Dinart
Derek Dinart
VRVirginie Rondeau
Virginie Rondeau
CBCarine Bellera
Carine Bellera

5 November 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
DDDerek Dinart
Derek Dinart
ISIsabelle Soubeyran
Isabelle Soubeyran
CBCarine Bellera
Carine Bellera
HEHélène Espérou
Hélène Espérou
TGthe MULTISARC study group
the MULTISARC study group
Background: Soft-tissue sarcomas (STS) represent a heterogeneous group of rare tumors including more than 70 different histological subtypes. High throughput molecular analysis (next generation sequencing exome [NGS]) is a unique opportunity to identify driver mutations that can change the usual one-size-fits-all treatment paradigm to a patient-driven therapeutic strategy. The primary objective of the MULTISARC trial is to assess whether NGS can be conducted for a large proportion of metastatic STS participants within a reasonable time, and, secondarily to determine whether a NGS-guided therapeutic strategy improves participant’s outcome. Methods: This is a randomized, multicentre, phase II/III trial inspired by the design of umbrella and biomarker-driven trials. The setting plans up to 17 investigational centres across France and the recruitment of 960 participants. Participants aged at least 18 years, with unresectable locally advanced and/or metastatic STS confirmed by the French sarcoma pathological reference network, are randomized according to 1:1 allocation ratio between the experimental arm “NGS” and the standard “No NGS”. NGS will be considered feasible if (i) NGS results are available and interpretable, and (ii) a report of exome sequencing including a clinical recommendation from a multidisciplinary tumor board is provided to investigators within 7 weeks from reception of the samples on the biopathological platform. A feasibility rate of more than 70% is expected (null hypothesis: 70% versus alternative hypothesis: 80%). In terms of care, participants randomized in “No NGS” arm and who fail treatment will be able to switch to the NGS arm at the request of the investigator. Discussion: The MULTISARC trial is a prospective study designed to provide high-level evidence to support the implementation of NGS in routine clinical practice for advanced STS participants, on a large scale. Trial registration: clinicaltrial.gov NCT03784014.

22 November 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CBCamille Baudelin
Camille Baudelin
Paul SargosPaul Sargos
Paul Sargos
DDDerek Dinart
Derek Dinart
CHChristophe Hennequin
Christophe Hennequin
DTDiego Teyssonneau
Diego Teyssonneau
GRGuilhem Roubaud
Guilhem Roubaud

8 September 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
LMLucie Meynard
Lucie Meynard
DDDerek Dinart
Derek Dinart
BDBlandine Delaunay
Blandine Delaunay
AFAude Fléchon
Aude Fléchon
CSCarolina Saldana
Carolina Saldana
GRGuilhem Roubaud
Guilhem Roubaud

24 June 2020 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
DDDerek Dinart
Derek Dinart
JFJ. Fraisse
J. Fraisse
DTD. Tosi
D. Tosi
AMAudrey Mauguen
Audrey Mauguen
CTC. Touraine
C. Touraine
CMCaroline Mollevi
Caroline Mollevi
Background: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling of the dose-toxicity relationship have been developed. The main ones are: the continual reassessment method (CRM), the escalation with overdose control (EWOC) method and, for late-onset and cumulative toxicities, the time-to-event continual reassessment method (TITE-CRM) and the time-to-event escalation with overdose control (TITE-EWOC) methods. The objective of this work was to perform a user-friendly R package that combines the latter model-guided adaptive designs.Results: GUIP1 is an R Graphical User Interface for dose escalation strategies in Phase 1 cancer clinical trials. It implements the CRM (based on Bayesian or maximum likelihood estimation), EWOC and TITE-CRM methods using the dfcrm and bcrm R packages, while the TITE-EWOC method has been specifically developed. The program is built using the TCL/TK programming language, which can be compiled via R software libraries (tcltk, tkrplot, tcltk2). GUIP1 offers the possibility of simulating and/or conducting and managing phase I clinical trials in real-time using file management options with automatic backup of study and/or simulation results.Conclusions: GUIP1 is implemented using the software R, which is widely used by statisticians in oncology. This package simplifies the use of the main model-based dose escalation methods and is designed to be fairly simple for beginners in R. Furthermore, it offers multiple possibilities such as a full traceability of the study. By including multiple innovative adaptive methods in a free and user-friendly program, we hope that GUIP1 will promote and facilitate their use in designing future phase I cancer clinical trials.

9 July 2021 in Biometrics
Verified
Journal Article
Closed access
PDF file
DDDerek Dinart
Derek Dinart
CBCarine Bellera
Carine Bellera
VRVirginie Rondeau
Virginie Rondeau